U.S. stock market update: ALT5 Sigma down 10.90%

U.S. Stock Market Midday Update Stocks with High Trading Volume in the Industry Eli Lilly rose 1.60%, with a trading volume of $1.043 billion. Based on recent important news: On September 9, Eli Lilly announced the launch of its artificial intelligence platform TuneLab, opening drug development models to biotechnology companies. This move drove the stock price up by 1.60%. Data source: Eli Lilly press release. On September 8, analysts maintained a buy rating for Eli Lilly, with a target price of $900, boosting market confidence. Data source: Deutsche Bank analysis report. On September 8, Eli Lilly reached a cooperation agreement with Circle Pharma to use the TuneLab platform to promote cancer therapy development. Data source: Circle Pharma announcement. Novo Nordisk fell 0.72%, with a trading volume of $665 million, and the trading volume increased. Based on recent key news: On September 8, Faruqi & Faruqi, LLP encouraged Novo Nordisk investors to contact them to discuss their options regarding a securities lawsuit. This news raised market concerns, leading to a decline in stock price. On September 8, Novo Nordisk partnered with Novozymes to explore new solutions for improving metabolic health. Although this is positive news, the market reaction was muted, failing to boost the stock price. On September 9, ICER released a preliminary report stating that Novo Nordisk's weight loss drug is cost-effective. This news had a limited impact on the stock price. The demand for GLP-1 drugs is strong, and the industry outlook is optimistic. Johnson & Johnson fell 0.72%, with increased trading volume. Based on recent important news: On September 9, Johnson & Johnson announced the appointment of former Sherwin-Williams CEO John Morikis to its board, aimed at strengthening corporate governance and leadership team strategy, resulting in a 0.8% drop in stock price. On September 9, the market remains optimistic about Johnson & Johnson's long-term growth potential, despite facing multiple compression risks, with its recent 24% increase seen as a re-rating of fundamental improvements. On September 8, Johnson & Johnson will speak at the upcoming Bernstein Annual Healthcare Forum, and the market's continued focus on its innovative healthcare solutions may influence stock price volatility. Biotechnology investments drive long-term growth in pharmaceutical stocks. Stocks with High Market Capitalization in the Industry AstraZeneca fell 0.69%, with a market capitalization of $251.3 billion. Based on recent key news: On September 9, AstraZeneca's Tagrisso combined chemotherapy showed significant survival advantages in the final survival analysis, leading to stock price fluctuations. Data showed that the median survival for combination therapy was 47.5 months, compared to 37.6 months for monotherapy. On September 8, analyst reports indicated that AstraZeneca's stock price is still 12.96% below the consensus target price, suggesting further growth potential On September 7th, AstraZeneca's Tagrisso drug showed a higher rate of side effects in a study, affecting investor sentiment. The pharmaceutical industry performed well overall, with a stable macroeconomic environment